SUN PHARMACEUTICAL INDUSTRIES Financial Statement Analysis
|
||
|
The Revenues of SUN PHARMACEUTICAL INDUSTRIES have increased by 11.19% YoY .
The Earnings Per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES has increased by 5.03 % YoY. |
||
SUN PHARMACEUTICAL INDUSTRIES Last 5 Annual Financial Results
[BOM: 524715|NSE : SUNPHARMA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹58,462 Cr | ₹52,578 Cr | ₹48,497 Cr | ₹43,886 Cr | ₹38,654 Cr |
| Expenses | ₹41,971 Cr | ₹37,492 Cr | ₹35,748 Cr | ₹32,298 Cr | ₹28,773 Cr |
| Operating Profit (Excl OI) | ₹16,491 Cr | ₹15,086 Cr | ₹12,749 Cr | ₹11,588 Cr | ₹9,882 Cr |
| Other Income | ₹3,212 Cr | ₹2,151 Cr | ₹1,628 Cr | ₹694 Cr | ₹1,437 Cr |
| Interest | ₹339 Cr | ₹231 Cr | ₹238 Cr | ₹172 Cr | ₹127 Cr |
| Depreciation | ₹2,938 Cr | ₹2,575 Cr | ₹2,557 Cr | ₹2,529 Cr | ₹2,144 Cr |
| Profit Before Tax | ₹15,119 Cr | ₹13,752 Cr | ₹11,088 Cr | ₹9,408 Cr | ₹4,481 Cr |
| Profit After Tax | ₹11,565 Cr | ₹10,980 Cr | ₹9,648 Cr | ₹8,561 Cr | ₹3,406 Cr |
| Consolidated Net Profit | ₹11,479 Cr | ₹10,929 Cr | ₹9,576 Cr | ₹8,474 Cr | ₹3,273 Cr |
| Earnings Per Share (Rs) | ₹47.84 | ₹45.55 | ₹39.91 | ₹35.32 | ₹13.64 |
| PAT Margin (%) | 19.78 | 20.88 | 19.89 | 19.51 | 5.07 |
| ROE(%) | 14.85 | 16.16 | 16.13 | 16.46 | 7.21 |
| ROCE(%) | 19.11 | 19.89 | 17.60 | 17.24 | 9.28 |
| Total Debt/Equity(x) | 0.05 | 0.03 | 0.04 | 0.11 | 0.02 |
Key Financials |
||
| Market Cap | : | ₹ 461,841.3 Cr |
| Revenue (TTM) | : | ₹ 59,910.5 Cr |
| Net Profit(TTM) | : | ₹ 12,172.7 Cr |
| EPS (TTM) | : | ₹ 50.7 |
| P/E (TTM) | : | 37.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -1.3% | 21.5% |
| DIVIS LABORATORIES | 2.7% | 16.1% | 38.6% |
| TORRENT PHARMACEUTICALS | -1.5% | -3.3% | 35.6% |
| CIPLA | -0.7% | 1.4% | -2% |
| DR REDDYS LABORATORIES | 3.9% | -1.8% | 0.4% |
| MANKIND PHARMA | -0.7% | -4.9% | -4.9% |
| LUPIN | -1.8% | -10.6% | 16.2% |
| ZYDUS LIFESCIENCES | 1.7% | -1.2% | 24.1% |
| AUROBINDO PHARMA | 0.7% | 7.1% | 54.9% |
SUN PHARMACEUTICAL INDUSTRIES Revenues
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 11.19 % |
| 5 Yr CAGR | 10.90 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹58,462 Cr | 11.19 | |
| Mar2025 | ₹52,578 Cr | 8.42 | |
| Mar2024 | ₹48,497 Cr | 10.51 | |
| Mar2023 | ₹43,886 Cr | 13.53 | |
| Mar2022 | ₹38,654 Cr | - | |
SUN PHARMACEUTICAL INDUSTRIES Operating Profit
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 9.31 % |
| 5 Yr CAGR | 13.66 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹16,491 Cr | 9.31 | |
| Mar2025 | ₹15,086 Cr | 18.33 | |
| Mar2024 | ₹12,749 Cr | 10.02 | |
| Mar2023 | ₹11,588 Cr | 17.26 | |
| Mar2022 | ₹9,882 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -1.67 % |
| 5 Yr CAGR | 2.50 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 28.21% | -1.67 | |
| Mar2025 | 28.69% | 9.13 | |
| Mar2024 | 26.29% | -0.42 | |
| Mar2023 | 26.4% | 3.29 | |
| Mar2022 | 25.56% | - | |
SUN PHARMACEUTICAL INDUSTRIES Profit After Tax
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 5.04 % |
| 5 Yr CAGR | 36.85 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹11,479 Cr | 5.04 | |
| Mar2025 | ₹10,929 Cr | 14.12 | |
| Mar2024 | ₹9,576 Cr | 13.01 | |
| Mar2023 | ₹8,474 Cr | 158.91 | |
| Mar2022 | ₹3,273 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -5.27 % |
| 5 Yr CAGR | 40.54 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 19.78 % | -5.27 | |
| Mar2025 | 20.88 % | 4.98 | |
| Mar2024 | 19.89 % | 1.95 | |
| Mar2023 | 19.51 % | 284.81 | |
| Mar2022 | 5.07 % | - | |
SUN PHARMACEUTICAL INDUSTRIES Earnings Per Share (EPS)
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 5.03 % |
| 5 Yr CAGR | 36.85 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹48 | 5.03 | |
| Mar2025 | ₹46 | 14.13 | |
| Mar2024 | ₹40 | 13.00 | |
| Mar2023 | ₹35 | 158.94 | |
| Mar2022 | ₹14 | - | |
SUN PHARMACEUTICAL INDUSTRIES Return on Capital Employed (ROCE)
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | -3.92 % |
| 5 Yr CAGR | 19.79 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 19.11% | -3.92 | |
| Mar2025 | 19.89% | 13.01 | |
| Mar2024 | 17.6% | 2.09 | |
| Mar2023 | 17.24% | 85.78 | |
| Mar2022 | 9.28% | - | |
SUN PHARMACEUTICAL INDUSTRIES Share Price vs Sensex
| Current Share Price | : | ₹1,924.9 |
| Current MarketCap | : | ₹ 461,841.3 Cr |
| Updated EOD on | : | Aug 14,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% |
-1.3% |
21.5% |
| SENSEX | -0.6% |
1.1% |
-3.2% |
SUN PHARMACEUTICAL INDUSTRIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 200 EQUAL WEIGHT | -0.2% | 1.9% | 9.6% |
| BSE INDIA SECTORS LEADERS | -0.3% | 2% | 0.5% |
| BSE 1000 | -0.3% | 1.7% | 4.4% |
| BSE 250 LARGEMIDCAP INDEX | -0.4% | 1.7% | 3.4% |
| BSE 500 | -0.4% | 1.6% | 3.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY LARGEMIDCAP 250 | -0.2% | 1.4% | 6.2% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.3% | 1.2% | 7.3% |
| NIFTY PHARMA | -0.4% | 1.7% | 22.9% |
| NIFTY500 MULTICAP 50:25:25 | -0.4% | 1.3% | 5.8% |
| NIFTY 500 EQUAL WEIGHT | -0.5% | 1.1% | 7.9% |
You may also like the below Video Courses
FAQ about SUN PHARMACEUTICAL INDUSTRIES Financials
How the annual revenues of SUN PHARMACEUTICAL INDUSTRIES have changed ?
The Revenues of SUN PHARMACEUTICAL INDUSTRIES have increased by 11.19% YoY .
How the Earnings per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES have changed?
The Earnings Per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES has increased by 5.03 % YoY .
Check out Intrinsic Value of Peers of SUN PHARMACEUTICAL INDUSTRIES
Compare Stock Analytics of Peers of SUN PHARMACEUTICAL INDUSTRIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
